ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XBIO vs MRK // EV/EBITDA & P/E VALUATION

Xenetic Biosciences Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: XBIO 1 — MRK 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XBIO VS. MRK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XBIO MRK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 74.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -30.30% 20.70% -51.00 MRK /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 15.3x — TIE /valuation <GO>
Free Cash Flow Yield — 3.42% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.30% -94.30 MRK /operating-margins <GO>
Net Profit Margin -60.00% 28.10% -88.10 MRK /net-margins <GO>
Revenue Growth (YoY) 19.00% 1.30% +17.70 XBIO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.26% -2.26 MRK /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.19 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 MRK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.3 51.7 -5.40 MRK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.4x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.0M $361.02B -$361.02B MRK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XBIO REV MRK REV XBIO GROSS % MRK GROSS % XBIO FCF MRK FCF
FY 2025 $3.0M $65.01B — 74.8% -$2.3M $12.36B
FY 2024 $2.5M $64.17B — 76.3% -$2.8M $18.10B
FY 2023 $2.5M $60.12B — — -$4.1M $10.30B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XBIO // BETA —
MRK // BETA 0.92